Clinical Trial Update: Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating genomic and transcriptomic predictors of sequential sensitivity to trastuzumab deruxtecan (T-DXd) in ER+/HER2-low metastatic b…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)

Snippet

Sponsor: British Columbia Cancer Agency | Conditions: Breast Cancer | Phase 2 | Status: RECRUITING